- Compliance. Investigators are responsible for protocol compliance, and sponsors must bring non-compliant investigators back into compliance or discontinue study drug shipments. Collection, classification, categorization, trending, and tracking are required to assess compliance; response is required to bring investigators back into compliance.
- Reporting. The investigator is required to document and explain deviations from the approved protocol, report changes made to eliminate "immediate hazards to subjects," and report "unanticipated problems involving risks to human subjects." Sponsors are also required to report important protocol deviations in the Clinical Study Report. To distinguish between these reporting requirements, we must collect, classify, and categorize.
- Analysis. Only subjects with the required minimal exposure to the treatment regimen, sufficient data to analyze, and "the absence of any major protocol violations, including the violation of entry criteria" are included in the per-protocol analysis. To identify subjects that do not meet criteria, collection and classification are required.
Ready Room Blog
Protocol Deviations: Three Objectives
Listen to article
Audio generated by DropInBlog's Blog Voice AI™ may have slight pronunciation nuances. Learn more
Yesterday, we started a series of posts on protocol deviations by looking at how they are handled in GCP and regulations. Today, we ask our favorite question: Why do we collect, classify, categorize, trend, track, and respond to protocol deviations?
The regulations imply the following reasons:
Proven inspection management for the life Sciences industry
Biotech, pharmaceutical, medical device, CMOs, CROs, and laboratories big and small are getting ready with Ready Room.